A detailed history of Quadrant Capital Group LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,512 shares of AVXL stock, worth $13,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,512
Previous 1,512 -0.0%
Holding current value
$13,048
Previous $6,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$3.39 - $5.02 $5,125 - $7,590
1,512 New
1,512 $6,000
Q4 2023

Feb 08, 2024

BUY
$5.04 - $9.95 $433 - $855
86 New
86 $0
Q1 2018

May 10, 2018

SELL
$2.32 - $3.44 $3,955 - $5,865
-1,705 Closed
0 $0
Q2 2017

Aug 15, 2017

BUY
N/A
1,705
1,705 $9,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.